Introduction
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that is characterised by raised blood glucose levels due to resistance to the action of insulin. T2DM represents a large clinical burden; approximately 2.9 million people were diagnosed with T2DM in 2013 in the UK, 1 and treating T2DM and its complications is estimated to cost £12 billion annually.
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A step-wise approach to treatment is typically used alongside lifestyle changes, to help patients achieve target glycated haemoglobin (HbA1c) levels. First-line therapy is usually metformin (met), followed by adding on a sulphonylurea (SU) for second-line. Current third-line options to create a triple therapy regimen consist of either adding oral agents (dipeptidyl peptidase-4 inhibitors [DPP4i] or thiazolidinedione), or injectables (insulin or glucagon-like peptide-1 [GLP-1] analogues). Saxagliptin belongs to the DPP4i class, and acts by inhibiting the DPP4 enzyme in order to prolong incretin hormone influence on enhancing blood glucose levels. Saxagliptin is licensed as combination therapy with met+SU, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control. The economic evaluation presented below formed the basis of a submission to the Scottish Medicines Consortium (SMC) for saxagliptin in the indication described above.
Objectives
To evaluate the cost of using saxagliptin, compared to sitagliptin and linagliptin, when used as triple therapy in combination with met+SU for the treatment of patients with T2DM who are inadequately controlled on met+SU alone.
Methods

Comparative effectiveness
A systematic review carried out by the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2010 and updated independently by AstraZeneca with support from ICON Epidemiology in 2013 was used to identify the studies that provided the data for the indirect treatment comparison (ITC). The review addressed the question: "What is the comparative efficacy and safety of third-line anti-diabetes drugs in adults with T2DM experiencing inadequate glycaemic control on metformin and a sulfonylurea?".
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-A single study for each of the DPP4i's included in the economic evaluation was identified and used to source data for the adjusted ITC.
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-The studies identified were all placebo-controlled; no direct head-to-head data was available to compare the efficacy of saxagliptin to that of the comparators. The clinical effectiveness of the three DPP4i therapies was compared using data at 24 weeks, including the key T2DM outcomes of HbA1c, weight and episodes of hypoglycaemia.
-The adjusted ITC was conducted utilising methodology reported by Bucher et al.
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Economic evaluation
Due to the ITC results, a cost-minimisation analysis over a 1-year time horizon was developed. Drug costs were considered in the model, sourced from the British National Formulary (Table 1) .
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Cost-minimisation analysis of saxagliptin compared to sitagliptin and linagliptin as triple therapy in combination with metformin and a sulphonylurea in the treatment of type 2 diabetes mellitus from a UK healthcare perspective The application of an annual discount rate of 3.5% and use of a longer time horizon (up to 5 years) were explored in a scenario analysis.
Results
Adjusted ITC
The ITC, which did not include any direct head-to-head data, found no statistically significant differences between saxagliptin compared to either sitagliptin or linagliptin in terms of effectiveness (as measured by Hb1Ac change from baseline and weight change from baseline). The ITCs also found saxagliptin to be at least as safe as the other therapies ( Table 2) . The studies were comparable with regard to their study design, population and duration; the baseline characteristics of the study populations were similar, primary endpoints were at 24 weeks, none of the studies used a treat-to-target design and although eligibility criteria differed slightly in terms of T2DM medications, in all three studies the participants had inadequate glycaemic control at the time of randomisation after stable dosing with met+SU.
Cost-minimisation
Saxagliptin was associated with a yearly cost of £410.80 per patient. The yearly cost per patient for sitagliptin was £432.38, and the yearly cost per patient for linagliptin was also £432.38, based on drug costs.
-Saxagliptin has similar costs compared to the other DPP4i's, offering a small saving of £21.58 per patient per year. Scenario analyses:
-When considering potential competitor price discounts, a discount of just less than 5% (4.99%) is cost-neutral in the cost-minimisation analysis (Table 3 ).
-A scenario considering a 5-year time horizon with an annual discount rate of 3.5% was tested. In this analysis, saxagliptin is associated with cost-savings of £97.43 per patient over 5 years compared to both sitagliptin and linagliptin (Figure 1) . Limitations of this cost-minimisation analysis include assumptions of 100% compliance and clinical equivalence in terms of adverse events (AEs).
-All three DPP4i's are available in tablet form and are orally administered once daily, and are therefore theoretically subject to the same level of treatment compliance and monitoring. Consequently, any differences in the overall total costs of treatment would only be expected to be due to variability in the individual drug prices for each DPP4i.
-Although the adjusted ITC results suggested a lower risk of any hypoglycaemic event with saxagliptin, a costminimisation was still conducted as there were no severe hypoglycaemic events reported for saxagliptin or sitagliptin and therefore any cost difference in hypoglycaemic events may be negligible.
-The adjusted ITC results also suggested lower overall odds of AEs and serious adverse events (SAEs) with saxagliptin versus sitagliptin and linagliptin, although the 95% confidence intervals for the comparison with linagliptin indicate that the odds ratio for SAEs is not statistically significant (Table 2) . However, the cost-minimisation model conservatively assumed no differences in AEs between treatments. 
Discussion
This analysis was performed to inform a submission to the SMC in 2013; saxagliptin was accepted for restricted use in adult patients aged 18 years and older with T2DM to improve glycaemic control as triple oral therapy in combination with met+SU when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
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-Only the DPP4i's that were accepted for use in Scotland at the time of the submission were therefore included in the analysis.
-The studies available to compare the effectiveness of the DPP4i's did not include any direct head-to-head comparisons of the DPP4i's. The cost-savings per patient over 5 years with the use of saxagliptin were modest, but may be important in a large patient population.
-For example, applying these savings to 5% of the estimated UK T2DM patient population, 1 would result in cost-savings of approximately £3.1 million after 1 year.
Conclusion
When used as part of a triple therapy regimen with met+SU, an ITC showed that saxagliptin appears to have clinical efficacy similar to sitagliptin and linagliptin. In this cost-minimisation, saxagliptin as triple therapy in combination with met+SU was shown to be a modestly costsaving treatment option from a UK healthcare perspective for patients with T2DM who are inadequately controlled on met+SU alone. 
